On October 15, 2024, Soleil Boughton, Chief Legal Officer of Hims & Hers Health Inc (HIMS, Financial), sold 2,339 shares of the company, according to a recent SEC Filing. Following this transaction, the insider now owns 172,274 shares of the company.
Hims & Hers Health Inc (HIMS, Financial) is a telehealth company that provides modern personalized health and wellness experiences to consumers. The company offers a broad range of prescription medications, over-the-counter treatments, and other healthcare products.
Over the past year, the insider has sold a total of 299,712 shares and has not made any purchases. This recent transaction continues a trend observed over the last year, where there have been 87 insider sells and only 1 insider buy at Hims & Hers Health Inc.
Shares of Hims & Hers Health Inc were trading at $20.41 on the day of the transaction. The company has a market cap of approximately $4.84 billion. The price-earnings ratio of the company stands at 279.50, significantly higher than the industry median of 18.03.
The stock's GF Value is estimated at $16.02, indicating that at a price of $20.41, Hims & Hers Health Inc is considered Significantly Overvalued with a price-to-GF-Value ratio of 1.27.
The GF Value is calculated based on historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from analysts.
This insider sale might be of interest to investors tracking insider behaviors and evaluating the valuation metrics and trends of Hims & Hers Health Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
